nach oben

Erschienen in:

01.03.2012 | Guideline

German S3-guidelines on the treatment of psoriasis vulgaris (short version)

verfasst von: A. Nast, W. H. Boehncke, U. Mrowietz, H. M. Ockenfels, S. Philipp, K. Reich, T. Rosenbach, A. Sammain, M. Schlaeger, M. Sebastian, W. Sterry, V. Streit, M. Augustin, R. Erdmann, J. Klaus, J. Koza, S. Müller, H. D. Orzechowski, S. Rosumeck, G. Schmid-Ott, T. Weberschock, B. Rzany

Erschienen in: Archives of Dermatological Research | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Psoriasis vulgaris is a common and often chronic inflammatory skin disease. The incidence of psoriasis in Western industrialized countries ranges from 1.5 to 2%. Patients afflicted with severe psoriasis vulgaris may experience a significant reduction in quality of life. Despite the large variety of treatment options available, patient surveys have revealed insufficient satisfaction with the efficacy of available treatments and a high rate of medication non-compliance (Richards et al. in J Am Acad Dermatol 41(4):581–583, 1999). To optimize the treatment of psoriasis in Germany, the Deutsche Dermatologische Gesellschaft (DDG) and the Berufsverband Deutscher Dermatologen (BVDD) have initiated a project to develop evidence-based guidelines for the management of psoriasis first published in 2006 and now updated in 2011. The Guidelines focus on induction therapy in cases of mild, moderate, and severe plaque-type psoriasis in adults. This short version of the guidelines presents the resulting series of therapeutic recommendations, which were based on a systematic literature search and discussed and approved by a team of dermatology experts. In addition to the therapeutic recommendations provided in this short version, the full version of the guidelines includes information on contraindications, adverse events, drug interactions, practicality, and costs, as well as detailed information on how best to apply the treatments described (for full version please see Nast et al. in JDDG Suppl 2:S1–S104, 2011 or http://www.psoriasis-leitlinie.de).

Nur mit Berechtigung zugänglich

Abe M, Ishibuchi H, Syuto T, Sogabe Y, Yokoyama Y, Ishikawa O (2007) Clinical usefulness and patient satisfaction for treatment with low-dose cyclosporin administration in patients with moderate psoriasis vulgaris. J Dermatol 34(5):290–293. doi:10.1111/j.1346-8138.2007.00275.x PubMedCrossRef

Abe M, Syuto T, Hasegawa M, Sogabe Y, Yokoyama Y, Ishikawa O (2006) Daily versus intermittent application of high-concentration tacalcitol ointment in combination with low-dose cyclosporin for psoriasis vulgaris. J Dermatol 33(2):108–111. doi:10.1111/j.1346-8138.2006.00022.x PubMedCrossRef

Agarwal R, Saraswat A, Kaur I, Katare OP, Kumar B (2002) A novel liposomal formulation of dithranol for psoriasis: preliminary results. J Dermatol 29(8):529–532PubMed

Agrup G, Agdell J (1985) A comparison between Antraderm stick (0.5 and 1%) and dithranol paste (0.125 and 0.25%) in the treatment of psoriasis. Br J Clin Pract 39(5):185–187PubMed

Altmeyer P, Hartwig R, Matthes U (1996) Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 patients. Hautarzt 47(3):190–196PubMedCrossRef

Altmeyer PJ, Matthes U, Pawlak F, Hoffmann K, Frosch PJ, Ruppert P, Wassilew SW, Horn T, Kreysel HW, Lutz G et al (1994) Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 30(6):977–981PubMedCrossRef

Amornpinyokeit N, Asawanonda P (2006) 8-Methoxypsoralen cream plus targeted narrowband ultraviolet B for psoriasis. Photodermatol Photoimmunol Photomed 22(6):285–289. doi:10.1111/j.1600-0781.2006.00249.x PubMedCrossRef

Andrys C, Borska L, Pohl D, Fiala Z, Hamakova K, Krejsek J (2007) Angiogenic activity in patients with psoriasis is significantly decreased by Goeckerman’s therapy. Arch Dermatol Res 298(10):479–483. doi:10.1007/s00403-006-0723-8 PubMedCrossRef

Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A (2005) Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64(8):1150–1157. doi:10.1136/ard.2004.032268 PubMedCrossRef

10.

Asawanonda P, Amornpinyokeit N, Nimnuan C (2008) Topical 8-methoxypsoralen enhances the therapeutic results of targeted narrowband ultraviolet B phototherapy for plaque-type psoriasis. J Eur Acad Dermatol Venereol 22(1):50–55. doi:10.1111/j.1468-3083.2007.02328.x PubMed

11.

Asawanonda P, Nateetongrungsak Y (2006) Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study. J Am Acad Dermatol 54(6):1013–1018. doi:10.1016/j.jaad.2006.01.004 PubMedCrossRef

12.

Bagatell F (1988) Management of psoriasis: a clinical evaluation of the dermatological patch, Actiderm™, over a topical steroid. Adv Therap 5(6):291–296

13.

Bagel J (2009) LCD plus NB-UVB reduces time to improvement of psoriasis vs NB-UVB alone. J Drugs Dermatol 8(4):351–357PubMed

14.

Barth J, Dietz O, Heilmann S, Kadner H, Kraensel H, Meffert H, Metz D, Pinzer B, Schiller F (1978) Photochemotherapy by 8-methoxypsoralen and UVA in psoriasis vulgaris—clinical experiences in 5 dermatological departments of GDR. Dermatol Monatsschr 164(6):401–407 (author’s translation)PubMed

15.

Bayard W, Hunziker T, Krebs A, Speiser P, Joshi R (1987) Peroral long-term treatment of psoriasis using fumaric acid derivatives. Hautarzt 38(5):279–285PubMed

16.

Belsito DV, Kechijian P (1982) The role of tar in Goeckerman therapy. Arch Dermatol 118(5):319–321PubMedCrossRef

17.

Berends MA, Driessen RJ, Langewouters AM, Boezeman JB, Van De Kerkhof PC, De Jong EM (2007) Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice. J Dermatolog Treat 18(2):76–83. doi:10.1080/09546630601121086 PubMedCrossRef

18.

Berg M, Ros AM (1994) Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen. Photodermatol Photoimmunol Photomed 10(5):217–220PubMed

19.

Berger K, Ehlken B, Kugland B, Augustin M (2005) Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges 3(7):511–518. doi:10.1111/j.1610-0387.2005.05729.x PubMedCrossRef

20.

Beutner K, Chakrabarty A, Lemke S, Yu K (2006) An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis. J Drugs Dermatol 5(4):357–360PubMed

21.

Bongiorno MR, Pistone G, Doukaki S, Arico M (2008) Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis. Dermatol Ther 21(Suppl 2):S15–S20. doi:10.1111/j.1529-8019.2008.00227.x

22.

Brazzelli V, Barbagallo T, Prestinari F, Rona C, De Silvestri A, Trevisan V, Borroni G (2005) Non-invasive evaluation of tacalcitol plus puva versus tacalcitol plus UVB-NB in the treatment of psoriasis: “right-left intra-individual pre/post comparison design”. Int J Immunopathol Pharmacol 18(4):755–760PubMed

23.

Brockow T, Schiener R, Franke A, Resch KL, Peter RU (2007) A pragmatic randomized controlled trial on the effectiveness of highly concentrated saline spa water baths followed by UVB compared to UVB only in moderate to severe psoriasis. J Altern Complement Med 13(7):725–732. doi:10.1089/acm.2007.7099 PubMedCrossRef

24.

Brockow T, Schiener R, Franke A, Resch KL, Peter RU (2007) A pragmatic randomized controlled trial on the effectiveness of low concentrated saline spa water baths followed by ultraviolet B (UVB) compared to UVB only in moderate to severe psoriasis. J Eur Acad Dermatol Venereol 21(8):1027–1037. doi:10.1111/j.1468-3083.2007.02152.x PubMedCrossRef

25.

Buckley DA, Healy E, Rogers S (1995) A comparison of twice-weekly MPD-PUVA and three times-weekly skin typing-PUVA regimens for the treatment of psoriasis. Br J Dermatol 133(3):417–422PubMedCrossRef

26.

Caca-Biljanovska NG, V’Lckova-Laskoska MT (2002) Management of guttate and generalized psoriasis vulgaris: prospective randomized study. Croat Med J 43(6):707–712PubMed

27.

Calzavara-Pinton P (1998) Narrow band UVB (311 nm) phototherapy and PUVA photochemotherapy: a combination. J Am Acad Dermatol 38(5 Pt 1):687–690 (pii:S0190-9622(98)70214-2)PubMedCrossRef

28.

Calzavara-Pinton P, Ortel B, Carlino A, Honigsmann H, De Panfilis G (1992) A reappraisal of the use of 5-methoxypsoralen in the therapy of psoriasis. Exp Dermatol 1(1):46–51PubMedCrossRef

29.

Calzavara-Pinton PG, Ortel B, Honigsmann H, Zane C, De Panfilis G (1994) Safety and effectiveness of an aggressive and individualized bath-PUVA regimen in the treatment of psoriasis. Dermatology 189(3):256–259PubMedCrossRef

30.

Camarasa JM, Ortonne JP, Dubertret L (2003) Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy. J Dermatolog Treat 14(1):8–13 (pii:EPP1D2VMP79MR4VG)PubMedCrossRef

31.

Campanati A, Goteri G, Simonetti O, Ganzetti G, Giuliodori K, Giuliano A, Sabato S, Stramazzotti D, Gulini E, Dusi D, De Blasio S, Fabris G, Offidani A (2009) Angiogenesis in psoriatic skin and its modifications after administration of etanercept: videocapillaroscopic, histological and immunohistochemical evaluation. Int J Immunopathol Pharmacol 22(2):371–377PubMed

32.

Caproni M, Antiga E, Melani L, Volpi W, Del Bianco E, Fabbri P (2009) Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol 29(2):210–214. doi:10.1007/s10875-008-9233-0 PubMedCrossRef

33.

Carboni I, De Felice C, De Simoni I, Soda R, Chimenti S (2004) Fumaric acid esters in the treatment of psoriasis: an Italian experience. J Dermatolog Treat 15(1):23–26. doi:10.1080/09541440042000269 PubMedCrossRef

34.

Carlin CS, Callis KP, Krueger GG (2003) Efficacy of acitretin and commercial tanning bed therapy for psoriasis. Arch Dermatol 139(4):436–442. doi:10.1001/archderm.139.4.436 PubMedCrossRef

35.

Carroll CL, Clarke J, Camacho F, Balkrishnan R, Feldman SR (2005) Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch Dermatol 141(1):43–46. doi:10.1001/archderm.141.1.43 PubMedCrossRef

36.

Cassano N, Loconsole F, Galluccio A, Miracapillo A, Pezza M, Vena GA (2006) Once-weekly administration of high-dosage etanercept in patients with plaque psoriasis: results of a pilot experience (power study). Int J Immunopathol Pharmacol 19(1):225–229PubMed

37.

Cassano N, Miracapillo A, Coviello C, Loconsole F, Bellino M, Vena GA (2006) Treatment of psoriasis vulgaris with the two-compound product calcipotriol/betamethasone dipropionate followed by different formulations of calcipotriol. Clin Drug Investig 26(4):227–233PubMedCrossRef

38.

Cassano N, Puglisi Guerra A, Malara C, Loconsole F, Galluccio A, Pezza M, Vena GA (2007) Re-induction as a possible alternative modality of dose escalation of infliximab: a prospective evaluation in a small series of psoriatic patients. Int J Immunopathol Pharmacol 20(3):647–650PubMed

39.

Chaidemenos GC, Mourellou O, Avgoustinaki N, Papakonstantinou M, Karakatsanis G, Katsambas A (2007) Intermittent vs. continuous 1-year cyclosporin use in chronic plaque psoriasis. J Eur Acad Dermatol Venereol 21:1203–1208PubMed

40.

Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB (2001) Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357(9271):1842–1847. doi:10.1016/S0140-6736(00)04954-0 PubMedCrossRef

41.

Chladek J, Simkova M, Vaneckova J, Hroch M, Chladkova J, Martinkova J, Vavrova J, Beranek M (2008) The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. Eur J Clin Pharmacol 64(4):347–355. doi:10.1007/s00228-007-0442-x PubMedCrossRef

42.

Chuang TY, Samson CR (1991) Clinical efficacy and safety of augmented betamethasone dipropionate ointment and diflorasone ointment for psoriasis—a multicentre, randomized, double-blinded study. J Dermatol Treat 2(2):63–66CrossRef

43.

Cohen AD, Shapiro J, Michael D, Hodak E, Van-Dijk D, Naggan L, Vardy DA (2008) Outcome of “short-term” Dead Sea climatotherapy for psoriasis. Acta Derm Venereol 88(1):90–91. doi:10.2340/00015555-0340 PubMedCrossRef

44.

Collins P, Rogers S (1992) Bath-water compared with oral delivery of 8-methoxypsoralen PUVA therapy for chronic plaque psoriasis. Br J Dermatol 127(4):392–395PubMedCrossRef

45.

Cooper EJ, Herd RM, Priestley GC, Hunter JA (2000) A comparison of bathwater and oral delivery of 8-methoxypsoralen in PUVA therapy for plaque psoriasis. Clin Exp Dermatol 25(2):111–114. doi:ced589[pii] PubMedCrossRef

46.

Costanzo A, Mazzotta A, Papoutsaki M, Nistico S, Chimenti S (2005) Safety and efficacy study on etanercept in patients with plaque psoriasis. Br J Dermatol 152(1):187–189. doi:10.1111/j.1365-2133.2005.06306.x PubMedCrossRef

47.

Coven TR, Burack LH, Gilleaudeau R, Keogh M, Ozawa M, Krueger JG (1997) Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol 133(12):1514–1522PubMedCrossRef

48.

De Leeuw J, Van Lingen RG, Both H, Tank B, Nijsten T, Martino Neumann HA (2009) A comparative study on the efficacy of treatment with 585 nm pulsed dye laser and ultraviolet B-TL01 in plaque type psoriasis. Dermatol Surg 35(1):80–91. doi:10.1111/j.1524-4725.2008.34386.x PubMedCrossRef

49.

de Mare S, Calis N, den Hartog G, van Erp PE, van de Kerkhof PC (1988) The relevance of salicylic acid in the treatment of plaque psoriasis with dithranol creams. Skin Pharmacol 1(4):259–264PubMedCrossRef

50.

Decroix J, Pres H, Tsankov N, Poncet M, Arsonnaud S (2004) Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis. Cutis 74(3):201–206PubMed

51.

Diel R, Hauer B, Loddenkemper R, Manger B, Kruger K (2009) Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases. Z Rheumatol 68(5):411–416. doi:10.1007/s00393-009-0475-x PubMedCrossRef

52.

Diette KM, Momtaz K, Stern RS, Arndt KA, Parrish JA (1984) Role of ultraviolet A in phototherapy for psoriasis. J Am Acad Dermatol 11(3):441–447PubMedCrossRef

53.

Douglas WS, Poulin Y, Decroix J, Ortonne JP, Mrowietz U, Gulliver W, Krogstad AL, Larsen FG, Iglesias L, Buckley C, Bibby AJ (2002) A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 82(2):131–135PubMedCrossRef

54.

Dover JS, McEvoy MT, Rosen CF, Arndt KA, Stern RS (1989) Are topical corticosteroids useful in phototherapy for psoriasis? J Am Acad Dermatol 20(5 Pt 1):748–754PubMedCrossRef

55.

Elder CA, Moore M, Chang CT, Jin J, Charnick S, Nedelman J, Cohen A, Guzzo C, Lowe N, Simpson K et al (1995) Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasis. J Clin Pharmacol 35(9):865–875PubMed

56.

Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH, Rocher LL, Wheeler S, Hamilton TA, Parish TG et al (1991) Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 324(5):277–284PubMedCrossRef

57.

Engst R, Huber J (1989) Results of cyclosporin treatment of severe, chronic psoriasis vulgaris. Hautarzt 40(8):486–489PubMed

58.

Erceg A, Bovenschen HJ, van de Kerkhof PC, Seyger MM (2006) Efficacy of the pulsed dye laser in the treatment of localized recalcitrant plaque psoriasis: a comparative study. Br J Dermatol 155(1):110–114. doi:10.1111/j.1365-2133.2006.07141.x PubMedCrossRef

59.

Ezquerra GM, Regana MS, Millet PU (2007) Combination of acitretin and oral calcitriol for treatment of plaque-type psoriasis. Acta Derm Venereol 87(5):449–450. doi:10.2340/00015555-0290 PubMedCrossRef

60.

Fabry H, Yawalkar SJ (1983) A comparative multicentre trial of halometasone ointment and fluocortolone plus fluocortolone caproate ointment in the treatment of psoriasis. J Int Med Res 11(Suppl 1):26–30PubMed

61.

Feldman SR, Mellen BG, Housman TS, Fitzpatrick RE, Geronemus RG, Friedman PM, Vasily DB, Morison WL (2002) Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study. J Am Acad Dermatol 46(6):900–906PubMedCrossRef

62.

Finzi AF, Mozzanica N, Cattaneo A, Chiappino G, Pigatto PD (1989) Effectiveness of cyclosporine treatment in severe psoriasis: a clinical and immunologic study. J Am Acad Dermatol 21(1):91–97PubMedCrossRef

63.

Finzi AF, Mozzanica N, Pigatto PD, Cattaneo A, Ippolito F (1993) Cyclosporine versus etretinate: Italian multicentre comparative trial in severe psoriasis. Dermatology 187(Suppl 1):8–18CrossRef

64.

Fleischer AB Jr, Clark AR, Rapp SR, Reboussin DM, Feldman SR (1997) Commercial tanning bed treatment is an effective psoriasis treatment: results from an uncontrolled clinical trial. J Invest Dermatol 109(2):170–174PubMedCrossRef

65.

Flytström I, Stenberg B, Svensson A, Bergbrant IM (2008) Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 158(1):116–121. doi:10.1111/j.1365-2133.2007.08284.x PubMed

66.

Fortune DG, Richards HL, Kirby B, Bowcock S, Main CJ, Griffiths CE (2002) A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol 146(3):458–465. doi:4622[pii] PubMedCrossRef

67.

Franchi C, Cainelli G, Frigerio E, Garutti C, Altomare GF (2004) Association of cyclosporine and 311 nM UVB in the treatment of moderate to severe forms of psoriasis: a new strategic approach. Int J Immunopathol Pharmacol 17(3):401–406PubMed

68.

Frappaz A, Thivolet J (1993) Calcipotriol in combination with PUVA: a randomized double blind placebo study in severe psoriasis. Eur J Dermatol 3:351–354

69.

Frost P, Horwitz SN, Caputo RV, Berger SM (1979) Tar gel-phototherapy for psoriasis. Combined therapy with suberythemogenic doses of fluorescent sunlamp ultraviolet radiation. Arch Dermatol 115(7):840–846PubMedCrossRef

70.

Gisondi P, Del Giglio M, Cotena C, Girolomoni G (2008) Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol 158(6):1345–1349. doi:10.1111/j.1365-2133.2008.08564.x PubMedCrossRef

71.

Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G (2008) Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr 88(5):1242–1247PubMed

72.

Goldinger SM, Dummer R, Schmid P, Prinz Vavricka M, Burg G, Lauchli S (2006) Excimer laser versus narrow-band UVB (311 nm) in the treatment of psoriasis vulgaris. Dermatology 213(2):134–139. doi:10.1159/000093852 PubMedCrossRef

73.

Gollnick H, Altmeyer P, Kaufmann R, Ring J, Christophers E, Pavel S, Ziegler J (2002) Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris. Dermatology 205(1):46–53PubMedCrossRef

74.

Gollnick H, Menter A (1999) Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis. Br J Dermatol 140(Suppl 54):18–23PubMedCrossRef

75.

Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, Heffernan M, Miller B, Hamlin R, Lim L, Zhong J, Hoffman R, Okun MM (2006) Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 55(4):598–606. doi:10.1016/j.jaad.2006.05.027 PubMedCrossRef

76.

Gordon PM, Diffey BL, Mattews JNS, Farr PM (1999) A randomised comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J Am Acad Dermatol 41:728–732PubMedCrossRef

77.

Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, Kavanaugh A (2009) Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373(9664):633–640. doi:10.1016/S0140-6736(09)60140-9 PubMedCrossRef

78.

Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, Bala M, Marano CW, Menter A (2004) Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51(4):534–542. doi:10.1016/j.jaad.2004.02.021 PubMedCrossRef

79.

Gottlieb AB, Ford RO, Spellman MC (2003) The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg 7(3):185–192. doi:10.1007/s10227-002-0114-5 PubMedCrossRef

80.

Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A, Gordon KB, Zitnik R (2003) A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 139(12):1627–1632. doi:10.1001/archderm.139.12.1627 (discussion 1632)PubMedCrossRef

81.

Green L, Sadoff W (2002) A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. J Cutan Med Surg 6(2):95–102. doi:10.1007/s10227-001-0031-z PubMedCrossRef

82.

Grossman RM, Thivolet J, Claudy A, Souteyrand P, Guilhou JJ, Thomas P, Amblard P, Belaich S, de Belilovsky C, de la Brassinne M et al (1994) A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol 31(1):68–74PubMedCrossRef

83.

Grundmann-Kollmann M, Ludwig R, Zollner TM, Ochsendorf F, Thaci D, Boehncke WH, Krutmann J, Kaufmann R, Podda M (2004) Narrowband UVB and cream psoralen–UVA combination therapy for plaque-type psoriasis. J Am Acad Dermatol 50(5):734–739. doi:10.1016/S0190 PubMedCrossRef

84.

Guenther L, Van de Kerkhof PC, Snellman E, Kragballe K, Chu AC, Tegner E, Garcia-Diez A, Springborg J (2002) Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 147(2):316–323PubMedCrossRef

85.

Guenther LC, Poulin YP, Pariser DM (2000) A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. Clin Ther 22(10):1225–1238PubMedCrossRef

86.

Gupta AK, Goldfarb MT, Ellis CN, Voorhees JJ (1989) Side-effect profile of acitretin therapy in psoriasis. J Am Acad Dermatol 20(6):1088–1093PubMedCrossRef

87.

Hacker SM, Rasmussen JE (1992) The effect of flash lamp-pulsed dye laser on psoriasis. Arch Dermatol 128(6):853–855PubMedCrossRef

88.

Halevy S, Giryes H, Friger M, Sukenik H (1997) Dead sea bath salt for the treatment of psoriasis vulgaris: a double-blind controlled study. J Eur Acad Dermatol Venereol 9(3):237–242CrossRef

89.

Hanke CW, Steck WD, Roenigk HH Jr (1979) Combination therapy for psoriasis. Psoralens plus long-wave ultraviolet radiation with betamethasone valerate. Arch Dermatol 115(9):1074–1077PubMedCrossRef

90.

Harari M, Novack L, Barth J, David M, Friger M, Moses SW (2007) The percentage of patients achieving PASI 75 after 1 month and remission time after climatotherapy at the Dead Sea. Int J Dermatol 46(10):1087–1091. doi:10.1111/j.1365-4632.2007.03278.x PubMedCrossRef

91.

Hashizume H, Ito T, Yagi H, Takigawa M, Kageyama H, Furukawa F, Hata M, Shirahama S, Tanaka M, Higashishiba T, Machida H, Tsushima T, Matsushita K (2007) Efficacy and safety of preprandial versus postprandial administration of low-dose cyclosporin microemulsion (Neoral) in patients with psoriasis vulgaris. J Dermatol 34(7):430–434. doi:10.1111/j.1346-8138.2007.00305.x PubMedCrossRef

92.

Henseler T, Wolff K, Honigsmann H, Christophers E (1981) Oral 8-methoxypsoralen photochemotherapy of psoriasis. The European PUVA study: a cooperative study among 18 European centres. Lancet 1(8225):853–857PubMedCrossRef

93.

Heydendael VM, Spuls PI, Opmeer BC, de Borgie CA, Reitsma JB, Goldschmidt WF, Bossuyt PM, Bos JD, de Rie MA (2003) Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 349(7):658–665. doi:10.1056/NEJMoa021359 PubMedCrossRef

94.

Higgins E, Munro C, Marks J, Friedmann PS, Shuster S (1989) Relapse rates in moderately severe chronic psoriasis treated with cyclosporin A. Br J Dermatol 121(1):71–74PubMedCrossRef

95.

Housman TS, Keil KA, Mellen BG, McCarty MA, Fleischer AB Jr, Feldman SR (2003) The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis. J Am Acad Dermatol 49(1):79–82. doi:10.1067/mjd.2003.417 PubMedCrossRef

96.

Housman TS, Pearce DJ, Feldman SR (2004) A maintenance protocol for psoriasis plaques cleared by the 308 nm excimer laser. J Dermatolog Treat 15(2):94–97. doi:10.1080/09546630310021947 PubMedCrossRef

97.

Hroch M, Chladek J, Simkova M, Vaneckova J, Grim J, Martinkova J (2008) A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment. J Eur Acad Dermatol Venereol 22(1):19–24. doi:10.1111/j.1468-3083.2007.02264.x PubMed

98.

Hutchinson PE, Marks R, White J (2000) The efficacy, safety and tolerance of calcitriol 3 microg/g ointment in the treatment of plaque psoriasis: a comparison with short-contact dithranol. Dermatology 201(2):139–145PubMedCrossRef

99.

Ilknur T, Akarsu S, Aktan S, Ozkan S (2006) Comparison of the effects of pulsed dye laser, pulsed dye laser + salicylic acid, and clobetasole propionate + salicylic acid on psoriatic plaques. Dermatol Surg 32(1):49–55PubMedCrossRef

100.

Jarratt MT, Clark SD, Savin RC, Swinyer LJ, Safley CF, Brodell RT, Yu K (2006) Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis. Cutis 78(5):348–354PubMed

101.

Kabat-Zinn J, Wheeler E, Light T, Skillings A, Scharf MJ, Cropley TG, Hosmer D, Bernhard JD (1998) Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergoing phototherapy (UVB) and photochemotherapy (PUVA). Psychosom Med 60(5):625–632PubMed

102.

Katugampola GA, Rees AM, Lanigan SW (1995) Laser treatment of psoriasis. Br J Dermatol 133(6):909–913PubMedCrossRef

103.

Katz HI, Tanner DJ, Cuffie CA, Brody NI, Garcia CJ, Lowe NJ, Medansky RS, Roth HL, Shavin JS, Swinyer LJ (1998) A comparison of the efficacy and safety of the combination mometasone furoate 0.1%/salicylic acid 5% ointment with each of its components in psoriasis. J Derm Treat 9(3):151–156CrossRef

104.

Kaufmann R, Bibby AJ, Bissonnette R, Cambazard F, Chu AC, Decroix J, Douglas WS, Lowson D, Mascaro JM, Murphy GM, Stymne B (2002) A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 205(4):389–393PubMedCrossRef

105.

Kaur J, Sharma VK, Sethuraman G, Tejasvi T (2008) Comparison of the efficacy of psoralen ultraviolet A with narrowband ultraviolet B phototherapy for the treatment of chronic plaque psoriasis in patients with skin types IV and V. Clin Exp Dermatol 33(4):513–515. doi:10.1111/j.1365-2230.2008.02718.x PubMedCrossRef

106.

Kaur M, Oliver B, Hu J, Feldman SR (2006) Nonlaser UVB-targeted phototherapy treatment of psoriasis. Cutis 78(3):200–203PubMed

107.

Khurshid K, Haroon TS, Hussain I, Pal SS, Jahangir M, Zaman T (2000) Psoralen-ultraviolet A therapy vs. psoralen-ultraviolet B therapy in the treatment of plaque-type psoriasis: our experience with Fitzpatrick skin type IV. Int J Dermatol 39(11):865–867PubMedCrossRef

108.

Kirby B, Buckley DA, Rogers S (1999) Large increments in psoralen–ultraviolet A (PUVA) therapy are unsuitable for fair-skinned individuals with psoriasis. Br J Dermatol 140(4):661–666PubMedCrossRef

109.

Kircik L, Bagel J, Korman N, Menter A, Elmets CA, Koo J, Yang YC, Chiou CF, Dann F, Stevens SR (2008) Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. J Drugs Dermatol 7(3):245–253PubMed

110.

Koc E, Tunca M, Akgul EO, Akar A, Kurt Y, Kurumlu Z, Erbil K, Kilic S (2009) Effects of etanercept on urine neopterin levels in patients with psoriasis in a controlled, open-label study. J Dermatol 36(4):191–196. doi:10.1111/j.1346-8138.2009.00622.x PubMedCrossRef

111.

Kolbach DN, Nieboer C (1992) Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment. J Am Acad Dermatol 27(5 Pt 1):769–771PubMedCrossRef

112.

Koo J, Blum RR, Lebwohl M (2006) A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes. J Am Acad Dermatol 55(4):637–641. doi:10.1016/j.jaad.2006.05.026 PubMedCrossRef

113.

Koo J, Cuffie CA, Tanner DJ, Bressinck R, Cornell RC, DeVillez RL, Edwards L, Breneman DL, Piacquadio DJ, Guzzo CA, Monroe EW (1998) Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study. Clin Ther 20(2):283–291PubMedCrossRef

114.

Koo JY, Lowe NJ, Lew-Kaya DA, Vasilopoulos AI, Lue JC, Sefton J, Gibson JR (2000) Tazarotene plus UVB phototherapy in the treatment of psoriasis. J Am Acad Dermatol 43(5 Pt 1):821–828. doi:10.1067/mjd.2000.107940 PubMedCrossRef

115.

Koo JY, Martin D (2001) Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis. Int J Dermatol 40(3):210–212PubMedCrossRef

116.

Korver JE, Vissers WH, van Rens DW, Pasch MC, van Erp PE, Boezeman JB, van De Kerkhof PC (2007) A double-blind, randomized quantitative comparison of calcitriol ointment and calcipotriol ointment on epidermal cell populations, proliferation and differentiation. Br J Dermatol 156(1):130–137. doi:10.1111/j.1365-2133.2006.07561.x PubMedCrossRef

117.

Kragballe K, Jansen CT, Geiger JM, Bjerke JR, Falk ES, Gip L, Hjorth N, Lauharanta J, Mork NJ, Reunala T et al (1989) A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study. Acta Derm Venereol 69(1):35–40PubMed

118.

Kragballe K, Noerrelund KL, Lui H, Ortonne JP, Wozel G, Uurasmaa T, Fleming C, Estebaranz JL, Hanssen LI, Persson LM (2004) Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 150(6):1167–1173. doi:10.1111/j.1365-2133.2004.05986.x PubMedCrossRef

119.

Laburte C, Grossman R, Abi-Rached J, Abeywickrama KH, Dubertret L (1994) Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol 130(3):366–375PubMedCrossRef

120.

Lago E, Carneiro S, Cuzzi T, Magalhaes G, Cassia F, Pessanha F, Ramos-e-Silva M (2007) Clinical and immunohistochemical assessment of the effect of cyclosporin in keratinocytes and dermal dendrocytes in psoriasis. J Cutan Pathol 34(1):15–21. doi:10.1111/j.1600-0560.2006.00571.x PubMedCrossRef

121.

Lebwohl M (2000) Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid. J Am Acad Dermatol 43(2 Pt 3):S43–S46PubMedCrossRef

122.

Lebwohl M, Sherer D, Washenik K, Krueger GG, Menter A, Koo J, Feldman SR (2002) A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol 41(5):269–274PubMedCrossRef

123.

Lebwohl M, Yoles A, Lombardi K, Lou W (1998) Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol 39(3):447–450PubMedCrossRef

124.

Lee CS, Koo J (2009) The efficacy of three class I topical synthetic corticosteroids, fluocinonide 0.1% cream, clobetasol 0.05% cream and halobetasol 0.05% cream: a Scholtz-Dumas bioassay comparison. J Drugs Dermatol 8(8):751–755PubMed

125.

Leenutaphong V, Nimkulrat P, Sudtim S (2000) Comparison of phototherapy two times and four times a week with low doses of narrow-band ultraviolet B in Asian patients with psoriasis. Photodermatol Photoimmunol Photomed 16(5):202–206PubMedCrossRef

126.

Lemme G, Campanati A, Paolinelli M, Offidani A (2007) Diffuse psoriasis plaque type and infliximab: our experience and review of literature. G Ital Dermatol Venereol 142:9–14

127.

Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371(9625):1665–1674. doi:10.1016/S0140-6736(08)60725-4 PubMedCrossRef

128.

Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349(21):2014–2022. doi:10.1056/NEJMoa030409 PubMedCrossRef

129.

Levell NJ, Shuster S, Munro CS, Friedmann PS (1995) Remission of ordinary psoriasis following a short clearance course of cyclosporin. Acta Derm Venereol 75(1):65–69PubMed

130.

LeVine MJ, Parrish JA (1982) The effect of topical fluocinonide ointment on phototherapy of psoriasis. J Invest Dermatol 78(2):157–159PubMedCrossRef

131.

Liao YH, Chiu HC, Tseng YS, Tsai TF (2007) Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(−1) ointment and tacrolimus 0.3 mg g(−1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. Br J Dermatol 157(5):1005–1012. doi:10.1111/j.1365-2133.2007.08201.x PubMedCrossRef

132.

Litjens NH, Nibbering PH, Barrois AJ, Zomerdijk TP, Van Den Oudenrijn AC, Noz KC, Rademaker M, Van De Meide PH, Van Dissel JT, Thio B (2003) Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines. Br J Dermatol 148(3):444–451PubMedCrossRef

133.

Lotti T, Tripo L, Grazzini M, Krysenka A, Buggiani G, De Giorgi V (2009) Focused UV-B narrowband microphototherapy (Biopsorin). A new treatment for plaque psoriasis. Dermatol Ther 22(4):383–385. doi:10.1111/j.1529-8019.2009.01250.x PubMedCrossRef

134.

Lowe N, Feldman SR, Sherer D, Weiss J, Shavin JS, Lin YL, Foley V, Soto P (2005) Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis. J Dermatolog Treat 16(3):158–164. doi:10.1080/09546630510041060 PubMedCrossRef

135.

Magliocco MA, Pandya K, Dombrovskiy V, Christiansen L, Wong Y, Gottlieb AB (2006) A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB phototherapy for moderate to severe psoriasis vulgaris. J Am Acad Dermatol 54(1):115–118. doi:10.1016/j.jaad.2005.09.012 PubMedCrossRef

136.

Mahrle G, Schulze HJ (1990) The effect of initial external glucocorticoid administration on cignolin treatment of psoriasis. Z Hautkr 65(3):282, 285–287

137.

Mahrle G, Schulze HJ, Farber L, Weidinger G, Steigleder GK (1995) Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 32(1):78–88PubMedCrossRef

138.

Markham T, Rogers S, Collins P (2003) Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxypsoralen psoralen-UV-A for the treatment of chronic plaque psoriasis. Arch Dermatol 139(3):325–328PubMedCrossRef

139.

Martin-Ezquerra G, Sanchez-Regana M, Umbert-Millet P (2007) Optimization of narrow-band uvb with a 5% oleic acid cream in the treatment of psoriasis. J Drugs Dermatol 6(3):290–292PubMed

140.

Martin Ezquerra G, Sanchez Regana M, Herrera Acosta E, Umbert Millet P (2006) Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques. J Drugs Dermatol 5(4):334–336PubMed

141.

McBride SR, Walker P, Reynolds NJ (2003) Optimizing the frequency of outpatient short-contact dithranol treatment used in combination with broadband ultraviolet B for psoriasis: a randomized, within-patient controlled trial. Br J Dermatol 149(6):1259–1265PubMedCrossRef

142.

Medansky RS, Cuffie CA, Tanner DJ (1997) Mometasone furoate 0.1%-salicylic acid 5% ointment twice daily versus fluocinonide 0.05% ointment twice daily in the management of patients with psoriasis. Clin Ther 19(4):701–709PubMedCrossRef

143.

Meffert H, Brautigam M, Farber L, Weidinger G (1997) Low-dose (1.25 mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile. Acta Derm Venereol 77(2):137–141PubMed

144.

Menter A, Abramovits W, Colon LE, Johnson LA, Gottschalk RW (2009) Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis. J Drugs Dermatol 8(1):52–57PubMed

145.

Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley LT, Arnold C, Gottlieb AB (2007) A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 56(1):31 e31–e15. doi:10.1016/j.jaad.2006.07.017

146.

Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, Papp K (2008) Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 58(1):106–115. doi:10.1016/j.jaad.2007.09.010 PubMedCrossRef

147.

Mittal R, Malhotra S, Pandhi P, Kaur I, Dogra S (2009) Efficacy and safety of combination acitretin and pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial. Arch Dermatol 145(4):387–393. doi:10.1001/archdermatol.2009.5 PubMedCrossRef

148.

Monastirli A, Georgiou S, Pasmatzi E, Sakkis T, Badavanis G, Drainas D, Sagriotis A, Tsambaos D (2002) Calcipotriol plus short-contact dithranol: a novel topical combination therapy for chronic plaque psoriasis. Skin Pharmacol Appl Skin Physiol 15(4):246–251PubMed

149.

Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia HA, Stevens SR (2007) A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 56(4):598–603. doi:10.1016/j.jaad.2006.09.002 PubMedCrossRef

150.

Morison WL, Momtaz K, Parrish JA, Fitzpatrick TB (1982) Combined methotrexate-PUVA therapy in the treatment of psoriasis. J Am Acad Dermatol 6(1):46–51PubMedCrossRef

151.

Mrowietz U, Christophers E, Altmeyer P (1998) Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study. Br J Dermatol 138(3):456–460PubMedCrossRef

152.

Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Sammain A, Schlaeger M, Sebastian M, Sterry W, Streit V, Augustin M, Erdmann R, Klaus J, Koza J, Muller S, Orzechowski HD, Rosumeck S, Schmid-Ott G, Weberschock T, Rzany B (2011) S3-guidelines for the treatment of psoriasis vulgaris. Update 2011. J Dtsch Dermatol Ges 9(Suppl 2):S1–S104. doi:10.1111/j.1610-0379.2011.07680.x PubMed

153.

Nast A, Erdmann R, Pathirana D, Rzany B (2008) Translating psoriasis treatment guidelines into clinical practice—the need for educational interventions and strategies for broad dissemination. J Eval Clin Pract 14(5):803–806. doi:10.1111/j.1365-2753.2008.00971.x PubMedCrossRef

154.

Nast A, Kopp I, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B (2007) German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 299(3):111–138. doi:10.1007/s00403-007-0744-y PubMedCrossRef

155.

Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B (2006) S3-Guidelines for the therapy of psoriasis vulgaris. J Dtsch Dermatol Ges 4(Suppl 2):S1–S126. doi:10.1111/j.1610-0387.2006.06172.x PubMed

156.

Nast A, Reytan N, Rosumeck S, Erdmann R, Rzany B (2008) Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry. J Eur Acad Dermatol Venereol 22(11):1337–1342. doi:10.1111/j.1468-3083.2008.02841.x PubMedCrossRef

157.

Nevitt GJ, Hutchinson PE (1996) Psoriasis in the community: prevalence, severity and patients’ beliefs and attitudes towards the disease. Br J Dermatol 135(4):533–537PubMedCrossRef

158.

Nugteren-Huying WM, van der Schroeff JG, Hermans J, Suurmond D (1990) Fumaric acid therapy in psoriasis; a double-blind, placebo-controlled study. Ned Tijdschr Geneeskd 134(49):2387–2391PubMed

159.

Nyfors A, Brodthagen H (1970) Methotrexate for psoriasis in weekly oral doses without any adjunctive therapy. Dermatologica 140(6):345–355PubMedCrossRef

160.

Ohtsuka T (2008) The correlation between response to oral cyclosporin therapy and systemic inflammation, metabolic abnormality in patients with psoriasis. Arch Dermatol Res 300:545–550PubMedCrossRef

161.

Orfanos CE, Steigleder GK, Pullmann H, Bloch PH (1979) Oral retinoid and UVB radiation: a new, alternative treatment for psoriasis on an out-patient basis. Acta Derm Venereol 59(3):241–244PubMed

162.

Ortonne JP, Kaufmann R, Lecha M, Goodfield M (2004) Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology 209(4):308–313. doi:10.1159/000080854 PubMedCrossRef

163.

Ortonne JP, van de Kerkhof PC, Prinz JC, Bieber T, Lahfa M, Rubins A, Wozel G, Lorette G (2006) 0.3% tacrolimus gel and 0.5% tacrolimus cream show efficacy in mild to moderate plaque psoriasis: results of a randomized, open-label, observer-blinded study. Acta Derm Venereol 86(1):29–33. doi:10.1080/00015550510039817 PubMed

164.

Pacifico A, Daidone R, Peris K (2006) A new formulation of an occlusive dressing containing betamethasone valerate 0.1% in the treatment of mild to moderate psoriasis. J Eur Acad Dermatol Venereol 20(2):153–157. doi:10.1111/j.1468-3083.2006.01387.x PubMedCrossRef

165.

Papoutsaki M, Chimenti MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A, Bianchi L, Chimenti S (2007) Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 57(2):269–275. doi:10.1016/j.jaad.2006.12.003 PubMedCrossRef

166.

Papp KA, Guenther L, Boyden B, Larsen FG, Harvima RJ, Guilhou JJ, Kaufmann R, Rogers S, van de Kerkhof PC, Hanssen LI, Tegner E, Burg G, Talbot D, Chu A (2003) Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 48(1):48–54. doi:10.1067/mjd.2003.130 PubMedCrossRef

167.

Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371(9625):1675–1684. doi:10.1016/S0140-6736(08)60726-6 PubMedCrossRef

168.

Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L (2005) A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 152(6):1304–1312. doi:10.1111/j.1365-2133.2005.06688.x PubMedCrossRef

169.

Park YK, Kim HJ, Koh YJ (1988) Combination of photochemotherapy (PUVA) and ultraviolet B (UVB) in the treatment of psoriasis vulgaris. J Dermatol 15(1):68–71PubMed

170.

Parker S, Coburn P, Lawrence C, Marks J, Shuster S (1984) A randomized double-blind comparison of PUVA-etretinate and PUVA-placebo in the treatment of chronic plaque psoriasis. Br J Dermatol 110(2):215–220PubMedCrossRef

171.

Parrish JA, Fitzpatrick TB, Tanenbaum L, Pathak MA (1974) Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med 291(23):1207–1211PubMedCrossRef

172.

Paul BS, Momtaz K, Stern RS, Arndt KA, Parrish JA (1982) Combined methotrexate–ultraviolet B therapy in the treatment of psoriasis. J Am Acad Dermatol 7(6):758–762PubMedCrossRef

173.

Peharda V, Gruber F, Prpic L, Kastelan M, Brajac I (2000) Comparison of mometasone fluroate 0.1% ointment and betamethasone dipropionate 0.05% ointment in the treatment of psoriasis vulgaris. Acta Derm Venereol Croat 8(4):223–226

174.

Peroni A, Gisondi P, Zanoni M, Girolomoni G (2008) Balneotherapy for chronic plaque psoriasis at Comano spa in Trentino, Italy. Dermatol Ther 21(Suppl 1):S31–S38. doi:10.1111/j.1529-8019.2008.00200.x PubMedCrossRef

175.

Petrozzi JW (1983) Topical steroids and UV radiation in psoriasis. Arch Dermatol 119(3):207–210PubMedCrossRef

176.

Petzelbauer P, Honigsmann H, Langer K, Anegg B, Strohal R, Tanew A, Wolff K (1990) Cyclosporin A in combination with photochemotherapy (PUVA) in the treatment of psoriasis. Br J Dermatol 123(5):641–647PubMedCrossRef

177.

Poulin YP (1999) Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study. Cutis 63(1):41–48PubMed

178.

Prins M, Swinkels OQ, Bouwhuis S, de Gast MJ, Bouwman-Boer Y, van der Valk PG, van de Kerkhof PC (2000) Dithranol in a cream preparation: disperse or dissolve? Skin Pharmacol Appl Skin Physiol 13(5):273–279PubMed

179.

Prins M, Swinkels OQ, Van de Kerkhof PC, Van der Valk PG (2001) The impact of the frequency of short contact dithranol treatment. Eur J Dermatol 11(3):214–218PubMed

180.

Radtke MA, Augustin M (2008) Economic considerations in psoriasis management. Clin Dermatol 26(5):424–431. doi:10.1016/j.clindermatol.2007.10.024 PubMedCrossRef

181.

Ramsay CA, Schwartz BE, Lowson D, Papp K, Bolduc A, Gilbert M (2000) Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study Group. Dermatology 200(1):17–24PubMedCrossRef

182.

Ranjan N, Sharma NL, Shanker V, Mahajan VK, Tegta GR (2007) Methotrexate versus hydroxycarbamide (hydroxyurea) as a weekly dose to treat moderate-to-severe chronic plaque psoriasis: a comparative study. J Dermatolog Treat 18(5):295–300. doi:10.1080/09546630701499291 PubMedCrossRef

183.

Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM (1999) Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41(3 Pt 1):401–407PubMedCrossRef

184.

Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366(9494):1367–1374. doi:10.1016/S0140-6736(05)67566-6 PubMedCrossRef

185.

Reitamo S, Spuls P, Sassolas B, Lahfa M, Claudy A, Griffiths CE (2001) Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 145(3):438–445PubMedCrossRef

186.

Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, Camez A (2008) Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 158(3):549–557. doi:10.1111/j.1365-2133.2007.08236.x PubMedCrossRef

187.

Richards HL, Fortune DG, Griffiths CE (2006) Adherence to treatment in patients with psoriasis. J Eur Acad Dermatol Venereol 20(4):370–379PubMedCrossRef

188.

Richards HL, Fortune DG, O’Sullivan TM, Main CJ, Griffiths CE (1999) Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 41(4):581–583PubMed

189.

Ring J, Kowalzick L, Christophers E, Schill WB, Schopf E, Stander M, Wolff HH, Altmeyer P (2001) Calcitriol 3 microg g-1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: results of a comparative study. Br J Dermatol 144(3):495–499PubMedCrossRef

190.

Robertson DB, McCarty JR, Jarratt M (1978) Treatment of psoriasis with 8-methoxypsoralen and sunlight. South Med J 71(11):1345–1349PubMedCrossRef

191.

Rogers S, Marks J, Shuster S, Briffa DV, Warin A, Greaves M (1979) Comparison of photochemotherapy and dithranol in the treatment of chronic plaque psoriasis. Lancet 1(8114):455–458PubMedCrossRef

192.

Rosina P, Giovannini A, Gisondi P, Girolomoni G (2009) Microcirculatory modifications of psoriatic lesions during topical therapy. Skin Res Technol 15(2):135–138. doi:10.1111/j.1600-0846.2008.00336.x PubMedCrossRef

193.

Salim A, Tan E, Ilchyshyn A, Berth-Jones J (2006) Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 154(6):1169–1174. doi:10.1111/j.1365-2133.2006.07289.x PubMedCrossRef

194.

Saraceno R, Andreassi L, Ayala F, Bongiorno MR, Giannetti A, Lisi P, Martini P, Peris K, Peserico A, Chimenti S (2007) Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial. J Dermatolog Treat 18(6):361–365. doi:10.1080/09546630701646156 PubMedCrossRef

195.

Saurat JH, Geiger JM, Amblard P, Beani JC, Boulanger A, Claudy A, Frenk E, Guilhou JJ, Grosshans E, Merot Y et al (1988) Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis. Dermatologica 177(4):218–224PubMedCrossRef

196.

Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Unnebrink K, Kaul M, Camez A (2008) Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 158(3):558–566. doi:10.1111/j.1365-2133.2007.08315.x PubMedCrossRef

197.

Schiener R, Brockow T, Franke A, Salzer B, Peter RU, Resch KL (2007) Bath PUVA and saltwater baths followed by UV-B phototherapy as treatments for psoriasis: a randomized controlled trial. Arch Dermatol 143(5):586–596. doi:10.1001/archderm.143.5.586 PubMedCrossRef

198.

Schmid-Ott G, Malewski P, Kreiselmaier I, Mrowietz U (2005) Psychosocial consequences of psoriasis—an empirical study of disease burden in 3753 affected people. Hautarzt 56(5):466–472. doi:10.1007/s00105-005-0906-9 PubMedCrossRef

199.

Schopf RE, Aust H, Knop J (2002) Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 46(6):886–891PubMedCrossRef

200.

Serwin AB, Chodynicka B (2007) Soluble tumour necrosis factor-alpha receptor type 1 as a biomarker of response to phototherapy in patients with psoriasis. Biomarkers 12(6):599–607. doi:10.1080/13547500701600597 PubMedCrossRef

201.

Serwin AB, Wasowicz W, Chodynicka B (2006) Selenium supplementation, soluble tumor necrosis factor-alpha receptor type 1, and C-reactive protein during psoriasis therapy with narrowband ultraviolet B. Nutrition 22(9):860–864. doi:10.1016/j.nut.2006.05.011 PubMedCrossRef

202.

Shupack JL, Jondreau L, Kenny C, Stiller MJ (1993) Diflorasone diacetate ointment 0.05% versus betamethasone dipropionate ointment 0.05% in moderate-severe plaque-type psoriasis. Dermatology 186(2):129–132PubMedCrossRef

203.

Smith CH, Jackson K, Bashir SJ, Perez A, Chew AL, Powell AM, Wain M, Barker JN (2006) Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. Br J Dermatol 155(1):160–169. doi:10.1111/j.1365-2133.2006.07316.x PubMedCrossRef

204.

Snellman E, Klimenko T, Rantanen T (2004) Randomized half-side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis. Acta Derm Venereol 84(2):132–137PubMedCrossRef

205.

Stein LF, Sherr A, Solodkina G, Gottlieb AB, Chaudhari U (2001) Betamethasone valerate foam for treatment of nonscalp psoriasis. J Cutan Med Surg 5(4):303–307. doi:10.1007/s10227-001-0006-0 PubMedCrossRef

206.

Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T (2004) Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 9(2):136–139. doi:10.1046/j.1087-0024.2003.09102.x PubMedCrossRef

207.

Stinco G, Lautieri S, Valent F, Patrone P (2007) Cutaneous vascular alterations in psoriatic patients treated with cyclosporine. Acta Derm Venereol 87(2):152–154. doi:10.2340/00015555-0216 PubMedCrossRef

208.

Svensson AR, Gisslen H, Nordin P, Gios I (1992) A comparative study of mometasone furoate ointment and betamethasone valerate ointment in patients with psoriasis vulgaris. Curr Ther Res Clin Exp 52(3):390–396CrossRef

209.

Swinkels OQ, Prins M, Kucharekova M, de Boo T, Gerritsen MJ, van der Valk PG, van de Kerkhof PC (2002) Combining lesional short-contact dithranol therapy of psoriasis with a potent topical corticosteroid. Br J Dermatol 146(4):621–626PubMedCrossRef

210.

Tabolli S, Alessandroni L, Didona B, Di Pietro C, Gisondi P, Rota L, Sampogna F, Abeni D (2009) A randomized controlled trial to evaluate short-term treatment with eosin vs. topical steroids in psoriasis. Clin Exp Dermatol 34(3):304–308. doi:10.1111/j.1365-2230.2008.02932.x PubMedCrossRef

211.

Taibjee SM, Cheung ST, Laube S, Lanigan SW (2005) Controlled study of excimer and pulsed dye lasers in the treatment of psoriasis. Br J Dermatol 153(5):960–966. doi:10.1111/j.1365-2133.2005.06827.x PubMedCrossRef

212.

Tausk F, Whitmore SE (1999) A pilot study of hypnosis in the treatment of patients with psoriasis. Psychother Psychosom 68(4):221–225PubMedCrossRef

213.

Thaci D, Brautigam M, Kaufmann R, Weidinger G, Paul C, Christophers E (2002) Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study. Dermatology 205(4):383–388PubMedCrossRef

214.

Thune P, Brolund L (1992) Short- and long-contact therapy using a new dithranol formulation in individually adjusted dosages in the management of psoriasis. Acta Derm Venereol Suppl (Stockh) 172:28–29

215.

Torras H, Aliaga A, Lopez-Estebaranz JL, Hernandez I, Gardeazabal J, Quintanilla E, Mascaro JM (2004) A combination therapy of calcipotriol cream and PUVA reduces the UVA dose and improves the response of psoriasis vulgaris. J Dermatolog Treat 15(2):98–103. doi:10.1080/09546630410023322 PubMedCrossRef

216.

Traupe H, Robra BP (2002) Gesundheitsberichterstattung des Bundes, vol Heft 11. Robert-Koch-Institut, Berlin

217.

Trehan M, Taylor CR (2002) Medium-dose 308-nm excimer laser for the treatment of psoriasis. J Am Acad Dermatol 47(5):701–708PubMedCrossRef

218.

Trott J, Gerber W, Hammes S, Ockenfels HM (2008) The effectiveness of PUVA treatment in severe psoriasis is significantly increased by additional UV 308-nm excimer laser sessions. Eur J Dermatol 18(1):55–60. doi:10.1684/ejd.2008.0311 PubMed

219.

Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R (2006) Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367(9504):29–35. doi:10.1016/S0140-6736(05)67763-X PubMedCrossRef

220.

ul Bari A, Iftikhar N, ber Rahman S, Iftikhar N, ber Rahman S (2005) Comparison of PUVA and UVB therapy in moderate plaque psoriasis. J Pak Assoc Dermatol 15:26–31

221.

Valbuena MC, Hernandez O, Rey M, Sanchez G, de Quintana LP (2007) Twice- vs. thrice-weekly MPD PUVA in psoriasis: a randomized-controlled efficacy study. Photodermatol Photoimmunol Photomed 23(4):126–129. doi:10.1111/j.1600-0781.2007.00294.x PubMedCrossRef

222.

van de Kerkhof PC, Cambazard F, Hutchinson PE, Haneke E, Wong E, Souteyrand P, Damstra RJ, Combemale P, Neumann MH, Chalmers RJ, Olsen L, Revuz J (1998) The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis. Br J Dermatol 138(1):84–89PubMedCrossRef

223.

van de Kerkhof PC, Green C, Hamberg KJ, Hutchinson PE, Jensen JK, Kidson P, Kragballe K, Larsen FG, Munro CS, Tillman DM (2002) Safety and efficacy of combined high-dose treatment with calcipotriol ointment and solution in patients with psoriasis. Dermatology 204(3):214–221PubMedCrossRef

224.

van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J (2008) Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 159(5):1177–1185. doi:10.1111/j.1365-2133.2008.08771.x PubMed

225.

van de Kerkhof PC, van der Valk PG, Swinkels OQ, Kucharekova M, de Rie MA, de Vries HJ, Damstra R, Oranje AP, de Waard-van der Spek FB, van Neer P, Lijnen RL, Kunkeler AC, van Hees C, Haertlein NG, Hol CW (2006) A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting. Br J Dermatol 155(4):800–807. doi:10.1111/j.1365-2133.2006.07393.x PubMedCrossRef

226.

van Lingen RG, de Jong EM, Berends MA, Seyger MM, van Erp PE, van de Kerkhof PC (2008) Good clinical response to anti-psoriatic treatment with adalimumab and methotrexate does not inflict a direct effect on compartmentalization of T-cell subsets: a pilot study. J Dermatolog Treat 19(5):284–287PubMedCrossRef

227.

van Lingen RG, Korver JE, van de Kerkhof PC, Berends MA, van Rens DW, Langewouters AM, Boezeman JB, Seyger MM, de Jong EM (2008) Relevance of compartmentalization of T-cell subsets for clinical improvement in psoriasis: effect of immune-targeted antipsoriatic therapies. Br J Dermatol 159(1):91–96. doi:10.1111/j.1365-2133.2008.08618.x PubMedCrossRef

228.

Vella Briffa D, Rogers S, Greaves MW, Marks J, Shuster S, Warin AP (1978) A randomized, controlled clinical trial comparing photochemotherapy with dithranol in the initial treatment of chronic plaque psoriasis. Clin Exp Dermatol 3(4):339–347PubMedCrossRef

229.

Vena GA, Cassano N, Agnusdei CP, Bellini M, Calabretta S, Centofani S, Cervadoro G, Coviello C, Curia S, Dattola S, de Caro C, del Brocco L, Donato L, Favero L, Ferrari A, Gianfaldoni R, Liguori G, Loconsole F, Lopreiato R, Malara G, Massimino SD, Nannipieri A, Pettinato M, Postiglione D, Postorioni C, Pronesti ME, Provenzano E, Puglisi Guerra A, Ricciuti F, Ruggiero G, Scudero A, Spitaleri S, Trinca Armati F, Valenti G, Vernaci R, Verrina F, Zagni GF, Zappala F (2005) Treatment of psoriasis vulgaris with calcipotriol betamethasone dipropionate combination followed by calcipotriol and assessment of the adjuvant basic use of urea-based emollients. Eur J Inflamm 3(1):37–41

230.

Vena GA, Cassano N, Loconsole F, Malara G, Sciarrone C, Puglisi Guerra A (2006) Sequential treatment of psoriasis with infliximab followed by cyclosporin. Preliminary results of an open-label prospective study. G Ital Dermatol Venereol 141:221–225

231.

Vena GA, Galluccio A, De Simone C, Mastrandrea V, Buquicchio R, La Greca S, Dattola S, Puglisi Guerra A, Donato L, Cantoresi F, De Pita O, Pezza M, M DA, Vernaci R, Miracapillo A, Valenti G, Cassano N (2009) A multicenter open-label experience on the response of psoriasis to Adalimumab and effect of dose escalation in non-responders: the Aphrodite project. Int J Immunopathol Pharmacol 22(1):227–233

232.

Veraldi S, Caputo R, Pacifico A, Peris K, Soda R, Chimenti S (2006) Short contact therapy with tazarotene in psoriasis vulgaris. Dermatology 212(3):235–237. doi:10.1159/000091250 PubMedCrossRef

233.

Vongthongsri R, Konschitzky R, Seeber A, Treitl C, Honigsmann H, Tanew A (2006) Randomized, double-blind comparison of 1 mg/L versus 5 mg/L methoxsalen bath-PUVA therapy for chronic plaque-type psoriasis. J Am Acad Dermatol 55(4):627–631. doi:10.1016/j.jaad.2006.05.024 PubMedCrossRef

234.

Weinstein GD, Frost P (1971) Methotrexate for psoriasis. A new therapeutic schedule. Arch Dermatol 103(1):33–38PubMedCrossRef

235.

Weinstein GD, Koo JY, Krueger GG, Lebwohl MG, Lowe NJ, Menter MA, Lew-Kaya DA, Sefton J, Gibson JR, Walker PS (2003) Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol 48(5):760–767. doi:10.1067/mjd.2003.103 PubMedCrossRef

236.

Weston WL, Fennessey PV, Morelli J, Schwab H, Mooney J, Samson C, Huff L, Harrison LM, Gotlin R (1988) Comparison of hypothalamus–pituitary–adrenal axis suppression from superpotent topical steroids by standard endocrine function testing and gas chromatographic mass spectrometry. J Invest Dermatol 90(4):532–535PubMedCrossRef

237.

White S, Vender R, Thaci D, Haverkamp C, Naeyaert J-M, Foster R, Martinez Escribano JA, Cambazard F, Bibby A (2006) Use of calcipotriene cream (Dovonex Cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex). Am J Clin Dermatol 7(3):177–184PubMedCrossRef

238.

Yones SS, Palmer RA, Garibaldinos TT, Hawk JL (2006) Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol 142(7):836–842. doi:10.1001/archderm.142.7.836 PubMedCrossRef

239.

Yoon HS, Youn JI (2007) A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis. J Dermatolog Treat 18(5):286–290. doi:10.1080/09546630701418747 PubMedCrossRef

240.

Youssef RM, Mahgoub D, Mashaly HM, El-Nabarawy E, Samir N, El-Mofty M (2008) Different narrowband UVB dosage regimens in dark skinned psoriatics: a preliminary study. Photodermatol Photoimmunol Photomed 24(5):256–259. doi:10.1111/j.1600-0781.2008.00371.x PubMedCrossRef

241.

Zachariae C, Mork NJ, Reunala T, Lorentzen H, Falk E, Karvonen SL, Johannesson A, Clareus B, Skov L, Mork G, Walker S, Qvitzau S (2008) The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol 88(5):495–501. doi:10.2340/00015555-0511 PubMedCrossRef

242.

Zaghloul SS, Goodfield MJ (2004) Objective assessment of compliance with psoriasis treatment. Arch Dermatol 140(4):408–414PubMedCrossRef

243.

Zhu X, Wang B, Zhao G, Gu J, Chen Z, Briantais P, Andres P (2007) An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 microg/g ointment vs. calcipotriol 50 microg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis. J Eur Acad Dermatol Venereol 21(4):466–472. doi:10.1111/j.1468-3083.2006.01913.x PubMed

Titel: German S3-guidelines on the treatment of psoriasis vulgaris (short version)
verfasst von: A. Nast
W. H. Boehncke
U. Mrowietz
H. M. Ockenfels
S. Philipp
K. Reich
T. Rosenbach
A. Sammain
M. Schlaeger
M. Sebastian
W. Sterry
V. Streit
M. Augustin
R. Erdmann
J. Klaus
J. Koza
S. Müller
H. D. Orzechowski
S. Rosumeck
G. Schmid-Ott
T. Weberschock
B. Rzany
Publikationsdatum: 01.03.2012
Verlag: Springer-Verlag
Erschienen in: Archives of Dermatological Research / Ausgabe 2/2012
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X
DOI: https://doi.org/10.1007/s00403-012-1214-8

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

16.04.2024 | Infektiologie | Nachrichten

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

German S3-guidelines on the treatment of psoriasis vulgaris (short version)

Abstract

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Dupilumab ist mit kutanen T-Zell-Lymphomen assoziiert

Chemotherapie mit Hindernissen

Update Dermatologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

A putative in vitro organotypic model of molting with human skin explants

The association of PASI scores with CRH-R1 expression in patients with psoriasis

Comparison of the spread of three botulinum toxin type A preparations

Psoriasis increased the risk of diabetes: a meta-analysis

Severe phenotypes in two Tunisian families with novel XPA mutations: evidence for a correlation between mutation location and disease severity

Endothelial and axon reflex vasodilatation to acetylcholine in rosacea-affected skin

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Dupilumab ist mit kutanen T-Zell-Lymphomen assoziiert

Chemotherapie mit Hindernissen

Update Dermatologie